Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

1 year ago 54
Read Entire Article
  1. Homepage
  2. Finance
  3. Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

Related

Israel Q1 GDP shrinks 3.3% annualised as Iran war weighs

Israel Q1 GDP shrinks 3.3% annualised as Iran war weighs

19 minutes ago 0
Brazil’s Lula aims to develop relationship with Trump, Washington Post reports

Brazil’s Lula aims to develop relationship with Trump, Washi...

19 minutes ago 0
Analysis-Bond yield spike is risk to unprepared equities market, investors warn

Analysis-Bond yield spike is risk to unprepared equities mar...

19 minutes ago 0

Trending

1. power outage near me
2. florida gators football
3. q day
4. rededicate 250
5. bank of america 7 eleven settlement
6. national grid
7. florida
8. acc baseball tournament
9. the handmaid's tale
10. man united vs nottm forest

Popular

College football by the odds: Vegas picks and preview of Ohio State vs. Notre Dame

College football by the odds: Vegas picks and preview of Ohi...

1 year ago 732
What is Tren de Aragua, the Venezuelan gang targeted by Trump?

What is Tren de Aragua, the Venezuelan gang targeted by Trum...

1 year ago 594
Taiwan slightly cuts 2025 GDP growth outlook amid Trump tariffs concern

Taiwan slightly cuts 2025 GDP growth outlook amid Trump tari...

1 year ago 460
Australian whose blood saved 2.4 million babies dies

Australian whose blood saved 2.4 million babies dies

1 year ago 458
What to do in Las Vegas this week: January 2-8

What to do in Las Vegas this week: January 2-8

1 year ago 407
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© Sincity Press 2026. All rights are reserved